Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease and Daffy for soap-free moisturising bar
Mankind Pharma has partnered with Dr Reddy’s Laboratories to acquire two of its brands Combihale and Daffy.
Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease. The market for this category is valued at ~ Rs 900 crores growing at 14 per cent (IQVIA). The acquisition of Combihale is expected to strengthen Mankind’s presence in the inhalation respiratory market segment. Daffy is a soap-free moisturising bar for infant babies. The total market for this category is valued at ~ Rs 1000 crores growing at 18 per cent (IQVIA).
Atish Majumdar, President, Mankind Pharma said, “We believe these brands have adequate potential to grow in the Indian market and the best part of the acquisition is that both these brands perfectly fit in our portfolio, and provides us an opportunity to grow and build the respiratory and dermatology business further.”
